Coherus BioSciences Inc at UBS Global Healthcare Conference Transcript
Good day, everybody, and welcome to UBS Global Healthcare Conference. Our next company presentation here is Coherus Biosciences. From the company, I have Chairman, President and CEO, Denny Lanfear; and Chief Commercial Officer, Paul Reider. Over to you, guys.
Thank you. Thank you, Ash, and thank you for the opportunity to speak again here at UBS in New York and see everyone in person. Let me first apprise you of the forward-looking statements. Just a quick overview.
Let me first apprise you the forward-looking statements and refer you to the company's SEC filings with respect to the various products, including YUSIMRY, CIMERLI and UDENYCA. Now I'll first talk a little bit about the strategy, and then we'll go on and talk a little bit about our approach to immunotherapy. And then my good friend, Paul will talk about the commercial execution, which is so important over the next 12 to 18 months for us and what we're going to have there.
So first, let me remind
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
